Cointime update: AriBio presented results from its global Phase III POLARIS-AD trial of oral drug candidate AR1001 at the CTAD conference, showing a 31% reduction in disease progression in the monotherapy population. The study enrolled 1,535 participants with early Alzheimer’s disease.
AriBio’s AR1001 Slows Alzheimer’s Progression by 31% in Phase III Trial
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
3h ago
HKMA Explores Agentic AI to Monitor Crypto Trades for Money Laundering
3h ago
Anthropic Expected to Price IPO Above Range at $80+ Per Share
4h ago
Coinbase AI Scam Defense Blocked $4.7M in Suspicious Transfers
4h ago
Nvidia CEO Jensen Huang Agrees to Testify at Senate Banking Committee
5h ago
Anthropic Existing Investors Plan Billions in IPO Share Purchase
6h ago
Analyst: Nvidia’s core business solid, AI infrastructure demand supports guidance